Peloton Wealth Strategists Has $1.17 Million Position in Eli Lilly and Company (NYSE:LLY)

Peloton Wealth Strategists trimmed its position in Eli Lilly and Company (NYSE:LLY) by 3.6% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,317 shares of the company’s stock after selling 49 shares during the quarter. Peloton Wealth Strategists’ holdings in Eli Lilly and Company were worth $1,167,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Drucker Wealth 3.0 LLC increased its holdings in shares of Eli Lilly and Company by 5.4% during the third quarter. Drucker Wealth 3.0 LLC now owns 509 shares of the company’s stock worth $451,000 after purchasing an additional 26 shares during the period. SGL Investment Advisors Inc. acquired a new stake in Eli Lilly and Company during the third quarter worth approximately $241,000. EWA LLC increased its stake in Eli Lilly and Company by 16.1% during the 3rd quarter. EWA LLC now owns 1,227 shares of the company’s stock worth $1,087,000 after acquiring an additional 170 shares during the period. Groupama Asset Managment raised its holdings in Eli Lilly and Company by 0.5% in the 3rd quarter. Groupama Asset Managment now owns 88,465 shares of the company’s stock valued at $784,000 after acquiring an additional 458 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. lifted its position in shares of Eli Lilly and Company by 3.4% during the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 343,586 shares of the company’s stock valued at $304,397,000 after acquiring an additional 11,273 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.1 %

Shares of Eli Lilly and Company stock opened at $826.71 on Monday. Eli Lilly and Company has a 52 week low of $561.65 and a 52 week high of $972.53. The stock has a 50 day moving average price of $842.70 and a two-hundred day moving average price of $872.01. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27. The stock has a market capitalization of $784.81 billion, a PE ratio of 89.37, a price-to-earnings-growth ratio of 3.13 and a beta of 0.41.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm’s quarterly revenue was up 20.4% on a year-over-year basis. During the same period last year, the business posted $0.10 earnings per share. As a group, equities analysts anticipate that Eli Lilly and Company will post 13.21 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be paid a dividend of $1.30 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.63%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 56.22%.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. The trade was a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.13% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on LLY. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a research report on Monday, November 4th. Barclays dropped their target price on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research report on Thursday, October 31st. Bank of America reduced their price target on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Finally, Guggenheim raised their target price on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,007.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.